✦ LIBER ✦

Peginterferon alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic Response

✍ Scribed by Stephen D.H. Malnick; Alon Basevitch

Book ID: 119759391
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 55 KB
Volume: 131
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2006.06.055

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Peginterferon Alfa-2b Therapy in Acute H

Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic Response

✍ Sanaa M. Kamal; Amr E. Fouly; Refaat R. Kamel; Bridgette Hockenjos; Ahmed Al Taw 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 243 KB

15 Peginterferon α-2b therapy in acute h

15 Peginterferon α-2b therapy in acute hepatitis C: Impact of onset and duration of therapy on sustained virologic response

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 122 KB

High sustained virologic response rates

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin

✍ Stefan Wirth; Carmen Ribes-Koninckx; Maria Angeles Calzado; Flavia Bortolotti; L 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 517 KB

Impact on adherence and sustained virolo

Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C

✍ L. CASTERA; A. CONSTANT; C. HENRY; P. CHAMPBENOIT; P.-H. BERNARD; V. DE LEDINGHE 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 488 KB

Peginterferon alpha-2a is associated wit

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials

✍ Tahany Awad; Kristian Thorlund; Goran Hauser; Davor Stimac; Mahasen Mabrouk; Chr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB 👁 1 views

A combination of weekly pegylated interferon (peginterferon) alpha and daily ribavirin represents the standard of care for the treatment of chronic hepatitis C according to current guidelines. It is not established which of the two licensed products (peginterferon alpha-2a or peginterferon alfa-2b)

481 FOUR-WEEK THERAPY WITH PEGINTERFERON

481 FOUR-WEEK THERAPY WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN EFFECTIVELY PREDICTS SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE AND PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV-1 TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

✍ J.M. Vierling; E.J. Lawitz; F. Poordad; M.S. Sulkowski; M. Bourliere; M. Buti; C 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB